Syros Accounts Payable vs Common Stock Shares Outstanding Analysis

SYRS Stock  USD 0.25  0.01  3.85%   
Syros Pharmaceuticals financial indicator trend analysis is much more than just breaking down Syros Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Syros Pharmaceuticals is a good investment. Please check the relationship between Syros Pharmaceuticals Accounts Payable and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Accounts Payable vs Common Stock Shares Outstanding

Accounts Payable vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Syros Pharmaceuticals Accounts Payable account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Syros Pharmaceuticals' Accounts Payable and Common Stock Shares Outstanding is 0.94. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Syros Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Syros Pharmaceuticals' Accounts Payable and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Syros Pharmaceuticals are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Accounts Payable i.e., Syros Pharmaceuticals' Accounts Payable and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.94
Relationship DirectionPositive 
Relationship StrengthVery Strong

Accounts Payable

An accounting item on the balance sheet that represents Syros Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Syros Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from Syros Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.Issuance Of Capital Stock is likely to gain to about 86.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2024.

Syros Pharmaceuticals fundamental ratios Correlations

0.810.910.440.810.850.9-0.47-0.830.560.840.890.750.810.880.970.030.690.55-0.160.850.880.920.860.180.94
0.810.920.280.660.880.71-0.12-0.820.640.490.730.740.520.860.780.430.720.580.120.690.810.90.74-0.250.76
0.910.920.180.80.90.87-0.24-0.910.720.680.870.80.740.910.860.190.720.66-0.140.860.860.980.890.060.91
0.440.280.18-0.010.10.31-0.130.08-0.410.280.330.210.20.350.450.20.28-0.430.53-0.080.280.21-0.060.070.33
0.810.660.8-0.010.830.78-0.53-0.850.810.730.680.440.770.750.790.070.720.76-0.430.910.740.790.910.090.75
0.850.880.90.10.830.73-0.39-0.930.770.660.720.660.650.760.850.150.740.79-0.280.880.80.90.9-0.20.77
0.90.710.870.310.780.73-0.16-0.750.560.630.970.640.760.860.780.140.730.45-0.090.80.730.830.810.360.97
-0.47-0.12-0.24-0.13-0.53-0.39-0.160.39-0.26-0.82-0.11-0.19-0.59-0.2-0.620.52-0.16-0.410.67-0.51-0.41-0.33-0.46-0.08-0.21
-0.83-0.82-0.910.08-0.85-0.93-0.750.39-0.89-0.7-0.75-0.76-0.65-0.76-0.810.01-0.55-0.90.37-0.96-0.86-0.92-0.97-0.01-0.82
0.560.640.72-0.410.810.770.56-0.26-0.890.450.520.560.450.540.52-0.010.410.94-0.440.850.70.710.860.010.6
0.840.490.680.280.730.660.63-0.82-0.70.450.620.60.860.610.9-0.380.420.53-0.540.790.750.740.770.30.7
0.890.730.870.330.680.720.97-0.11-0.750.520.620.760.710.850.780.080.650.44-0.040.780.740.830.80.360.98
0.750.740.80.210.440.660.64-0.19-0.760.560.60.760.510.640.72-0.140.270.53-0.080.680.810.810.710.230.78
0.810.520.740.20.770.650.76-0.59-0.650.450.860.710.510.670.81-0.120.70.42-0.510.770.580.710.770.30.73
0.880.860.910.350.750.760.86-0.2-0.760.540.610.850.640.670.820.310.740.470.070.740.760.880.770.030.86
0.970.780.860.450.790.850.78-0.62-0.810.520.90.780.720.810.82-0.040.640.56-0.240.820.870.90.830.090.84
0.030.430.190.20.070.150.140.520.01-0.01-0.380.08-0.14-0.120.31-0.040.51-0.130.66-0.14-0.010.14-0.07-0.550.05
0.690.720.720.280.720.740.73-0.16-0.550.410.420.650.270.70.740.640.510.31-0.040.580.420.630.61-0.220.62
0.550.580.66-0.430.760.790.45-0.41-0.90.940.530.440.530.420.470.56-0.130.31-0.550.860.680.70.86-0.090.53
-0.160.12-0.140.53-0.43-0.28-0.090.670.37-0.44-0.54-0.04-0.08-0.510.07-0.240.66-0.04-0.55-0.53-0.11-0.15-0.47-0.23-0.09
0.850.690.86-0.080.910.880.8-0.51-0.960.850.790.780.680.770.740.82-0.140.580.86-0.530.80.871.00.160.83
0.880.810.860.280.740.80.73-0.41-0.860.70.750.740.810.580.760.87-0.010.420.68-0.110.80.930.810.180.85
0.920.90.980.210.790.90.83-0.33-0.920.710.740.830.810.710.880.90.140.630.7-0.150.870.930.890.070.9
0.860.740.89-0.060.910.90.81-0.46-0.970.860.770.80.710.770.770.83-0.070.610.86-0.471.00.810.890.120.85
0.18-0.250.060.070.09-0.20.36-0.08-0.010.010.30.360.230.30.030.09-0.55-0.22-0.09-0.230.160.180.070.120.36
0.940.760.910.330.750.770.97-0.21-0.820.60.70.980.780.730.860.840.050.620.53-0.090.830.850.90.850.36
Click cells to compare fundamentals

Syros Pharmaceuticals Account Relationship Matchups

Syros Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets150.0M213.3M182.9M244.5M168.2M147.5M
Other Current Liab10.6M9.4M13.6M15.9M13.8M10.7M
Total Current Liabilities23.5M28.6M31.5M30.8M36.7M22.2M
Total Stockholder Equity79.2M90.6M85.2M127.7M16.7M15.8M
Other Liab22.6M29.6M3.0M24.5M28.1M29.5M
Net Tangible Assets79.2M125.4M106.1M148.6M170.9M179.4M
Property Plant And Equipment Net31.9M29.6M27.3M24.7M19.5M16.6M
Net Debt(15.5M)(107.8M)(27.1M)(103.9M)(77.5M)(81.3M)
Retained Earnings(293.0M)(377.0M)(463.6M)(558.2M)(722.8M)(686.7M)
Accounts Payable5.9M3.6M3.7M6.4M11.5M12.1M
Cash41.4M174.0M92.3M167.5M139.5M93.7M
Non Current Assets Total35.5M34.7M46.4M33.1M23.2M21.7M
Non Currrent Assets Other490K2.0M6.0M5.3M3.7M2.6M
Other Assets3.6M20.5M6.0M8.4M9.7M5.4M
Cash And Short Term Investments91.4M174.0M130.4M202.3M139.5M119.8M
Common Stock Total Equity26K34K43K56K20K28.2K
Common Stock Shares Outstanding4.0M4.6M6.3M12.6M28.3M29.7M
Short Term Investments39.8M49.8M50.0M0.038.1M34.8M
Liabilities And Stockholders Equity150.0M213.3M182.9M244.5M168.2M147.5M
Non Current Liabilities Total47.3M94.1M66.2M86.0M114.8M120.6M
Other Current Assets2.6M2.2M3.2M7.4M5.5M2.8M
Other Stockholder Equity372.1M467.5M548.8M685.8M739.4M377.3M
Total Liab70.8M122.7M97.7M116.8M151.5M159.1M
Property Plant And Equipment Gross31.9M29.6M37.1M37.2M27.1M19.9M
Total Current Assets114.5M178.6M136.6M211.4M145.0M125.8M
Accumulated Other Comprehensive Income24K0.0(79K)102K117.3K123.2K
Short Term Debt1.3M3.5M4.0M4.1M11.3M11.9M
Common Stock34K43K56K61K20K32.1K
Property Plant Equipment31.9M14.2M27.3M11.4M13.1M12.6M
Short Long Term Debt Total25.9M66.2M65.2M63.6M62.1M34.7M
Long Term Debt Total22K621K39.6M40.6M46.7M49.1M
Capital Surpluse296.1M372.1M467.5M685.8M788.7M828.2M
Current Deferred Revenue5.7M12.2M10.2M4.3M5.0M6.4M
Retained Earnings Total Equity(217.5M)(293.0M)(377.0M)(558.2M)(502.4M)(477.3M)
Capital Lease Obligations25.9M26.7M24.9M22.9M20.9M16.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.